pharma · Glycogen storage disease type II · Niemann-Pick disease
Sanofi Winthrop Industrie
CE SANOFI WINTHROP is a pharma organization headquartered in ANTONY, FR. Primary therapeutic focus areas include Glycogen storage disease type II, Niemann-Pick disease. NovaPharmaNews links 2 clinical program(s), 0 drug
ANTONY, FR HQ
12 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- ANTONY, FR
- Employees
- 12
- Programs
- 2
- Drugs
- 6
- Patents
- 0
Xenpozyme (olipudase alfa,GZ402665)
Phase 2 · small molecule · Niemann-Pick disease
Xenpozyme (olipudase alfa,GZ402665) for Niemann-Pick disease is a Phase 2 program (small_molecule) at Sanofi Winthrop Industrie with 1 ClinicalTrials.gov record(s).
Internal code PTA17397
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi Winthrop Industrie
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Niemann-Pick disease
- Status
- active
- Trials
- 1